Warning to Sun Life shareholders about Obatan LLC offer: Sun Life is not associated with Obatan LLC and does not recommend or endorse this offer. Investors should exercise caution with mini-tender offers. Learn more
Sun Life is ready to help Clients affected by recent severe storms, fires and other tragedies.
What's top of mind for Sun Life leaders? Sun Life's SVP of Health and Risk Solutions, Jennifer Collier and James Slotnick, Head of Government Relations share their perspectives on the evolving industry landscape in this 2023 Future Forecast.
Learn more about recently approved Hemgenix in the treatment of Hemophilia B, the gene therapy pipeline, the approval process, and what gene therapies are, in our second edition of the Introduction to Gene Therapies paper.
Every three minutes, someone in the U.S. is diagnosed with blood cancer. In our new Bright Paper, Sun Life shares research data and expert insights to help employers manage the impact of these high-cost claims, some of which can reach millions of dollars for treatment for a single patient, and get the best care for members.
For the past ten years, Sun Life has shared our data and insights with the self-funded marketplace to help employers and brokers understand trends around the highest-cost claims. While a lot has changed over the past decade, one thing has not: our commitment to providing you with actionable insights that can help you stay informed about conditions and medications most likely to result in a high-cost claim, and steps you can take to manage that risk as a self-funded employer.
A presentation and panel discussion on our high-cost claims and injectable drug trends analysis with insights on top claim conditions, million-dollar claims, injectable drugs, and trends we are seeing since the COVID-19 pandemic began.
A presentation and panel discussion on our annual Stop-Loss high-cost claims and injectable drugs trends analysis, the impact of COVID-19, million-dollar claims and more!
Webinar: Slide deck
Learn about the rising interest in self-funding and how employers of many sizes can transition to self-funding with group stop-loss captives, including different captive options and structures.
Every year, Sun Life shares latest insights from our claims experience to help self-funded employers prepare for potential high-cost claims. Our robust data set allows us to report on persistent themes, as well as emerging trends.
From a global perspective, 2020 was unlike any other year. For this year’s report, we felt it was important to show the consistent four year view that we have analyzed in past years, but we also wanted to highlight the single year 2020 data to explore the potential impacts of the pandemic on high-cost claim conditions.
A look inside Sun Life’s most recent million-dollar claim and injectable drug trend analysis with legislative updates on issues impacting self-funded employers.
Webinar: Slide deck
